{"id":"tissue-factor","name":"Tissue factor","symbol":"F3","route":"/targets/tissue-factor/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3541","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000117525","uniprot":"https://www.uniprot.org/uniprotkb/P13726/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P13726","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL4081","open-targets":"https://platform.opentargets.org/target/ENSG00000117525","civic":"https://civicdb.org/genes/2152/summary","oncokb":"https://www.oncokb.org/gene/F3","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=F3","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=F3","depmap":"https://depmap.org/portal/gene/F3?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000117525-F3","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/2152","omim":"https://www.omim.org/entry/134390"}],"products":[{"id":"tisotumab-vedotin","name":"Tisotumab vedotin","status":"approved","modality":"ADC","route":"/drugs/tisotumab-vedotin/"}],"trials":[{"id":"innovatv-301","name":"innovaTV 301 / ENGOT-cx12 / GOG-3057","nct":"NCT04697628","phase":"3","status":"positive"},{"id":"nct06459180","name":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With","nct":"NCT06459180","phase":"3","status":"active"},{"id":"nct03485209","name":"Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors","nct":"NCT03485209","phase":"2","status":"active"}],"pathways":[],"companies":["adcendo","genmab","pfizer","sutro-biopharma"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}